Search Results for “Gilead Sciences” – Page 7 – media

Rise in China’s Global Pharma Market up to $175 billion by 2022 – Market Prediction

Though the US stands first in the race in terms of sales and growth, it is highly believed that China would reach the peak in the pharma market by 2022. At present, since there has been a decrease in public health funding, there has been a slight fall in pharmerging countries like Brazil, Russia, India and China (BRIC). But it is believed that the condition of these pharmerging countries will improve in the next five years [1].
- Source: Ddu
- 822
- May 24, 2018
China Market Views pharmaceutical drugs
FDA ‘conflicted’ on Lilly and Incyte’s refiled baricitinib

Eli Lilly and Incyte’s second attempt to get U.S. approval of rheumatoid arthritis drug baricitinib could be scuppered again by lingering FDA concerns about safety. A briefing document published ahead of the April 23 advisory committee meeting on baricitinib suggests that Lilly and Incyte’s lightning-fast amendment and refile of the dossier hasn’t added enough data to persuade the FDA to change its stance on the risk of blood clots with the JAK inhibitor.
- Source: Fiercebiotech; new approvals
- 619
- April 24, 2018
baricitinib Eli Lilly FDA rheumatoid arthritis
Cellectis Snags $164 Million in IPO to Advance CAR-T Programs

Today the company has found some sure financial footing that will support its efforts through the remainder of the year. The company secured $163.7 million in an initial public offering. The funding will be used to continue the development of Cellectis’ off-the-shelf CAR-T products and drive them toward regulatory approval.
- Source: biospace
- 673
- April 13, 2018
CAR-T therapies Series
Shares of biotech Juno, already up 50% on deal hopes, skyrocket on actual Celgene $9 billion offer

Celgene agreed on Monday to buy the rest of Juno Therapeutics it doesn't already own for about $9 billion in cash to gain access to Juno's pipeline of CAR-T cancer drugs.
- Source: Cnbc
- 982
- January 24, 2018
cancer CAR–T Market Views
With 2-pronged filing, Novartis’ CAR-T med Kymriah aims to jump intoEurope with both feet

Novartis is blazing ahead with its bid to take its new CAR-T therapy, Kymriah, into new realms with a double-pronged approval application in Europe.
- Source: Fiercepharma
- 512
- November 10, 2017
CAR-T therapy Kymriah Novarti
Kite’s Yescarta™ (Axicabtagene Ciloleucel) Becomes First CAR T Therapy Approved by the FDA

Kite, a Gilead Company, announced that the U.S. Food and Drug Administration (FDA) has granted regular approval to Yescarta™ (axicabtagene ciloleucel), the first chimeric antigen receptor T cell (CAR T) therapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma (PMBCL), high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma (transformed follicular lymphoma, or TFL). Yescarta is not indicated for the treatment of patients with primary central nervous system lymphoma.
- Source: Businesswire
- 679
- October 20, 2017
B-cell lymphoma CAR–T FDA Market Views Yescarta
NIH accelerates the development of new cancer immunotherapy strategies for more patients

The National Institutes of Health(NIH) and 11 leading biopharmaceutical companies have launched the Partnership for Accelerating Cancer Therapies (PACT), a five-year public-private research collaboration totaling $215 million as part of the Cancer Moonshot.
- Source: nih.gov
- 550
- October 16, 2017
Market Views NIH PACT

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.